AGEN

SEC source: 0001193125-25-230100 · ownership.xml · nonDerivative · entry 1

HARRISON THOMAS L · CIK 0001247340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,079

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive their director fees in shares of Ageuns' common stock.

F2 · price: $5.01 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0001193125-25-230086 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,872.43

Underlying: Common Stock · 1,704.928 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $5.01 per Deferred Stock Unit acquired on July 1, 2025. The price of each Deferred Stock Unit acquired on October 1, 2025 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0001193125-25-213291 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 278,442

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending September 19, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.38 is the closing price of our Common Stock on September 19, 2025, the last trading day for the payroll date for the pay period ending September 19, 2025.

SEC source: 0001193125-25-199162 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 274,708

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending September 5, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.33 is the closing price of our Common Stock on September 5, 2025, the last trading day for the payroll date for the pay period ending September 5, 2025.

SEC source: 0000950170-25-111446 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 270,930

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending August 22, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.52 is the closing price of our Common Stock on August 22, 2025, the last trading day for the payroll date for the pay period ending August 22, 2025.

SEC source: 0000950170-25-106531 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 267,311

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending August 8, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.80 is the closing price of our Common Stock on August 8, 2025, the last trading day for the payroll date for the pay period ending August 8, 2025.

SEC source: 0000950170-25-099156 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 263,904

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 25, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $5.96 is the closing price of our Common Stock on July 25, 2025, the last trading day for the payroll date for the pay period ending July 25, 2025.

SEC source: 0000950170-25-095868 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 261,159

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 11, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $7.06 is the closing price of our Common Stock on July 11, 2025, the last trading day for the payroll date for the pay period ending July 11, 2025.

SEC source: 0000950170-25-093835 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,167.502

Underlying: Common Stock · 2,707.834 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.462 per Deferred Stock Unit acquired on July 1, 2025. The price of each Deferred Stock Unit acquired on July 1, 2025 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-25-095865 · ownership.xml · nonDerivative · entry 1

HARRISON THOMAS L · CIK 0001247340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,299

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive their director fees in shares of Ageuns' common stock.

F2 · price: $3.462 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0000950170-25-091637 · ownership.xml · nonDerivative · entry 2

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 258,842

F3 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 27, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F4 · price: $4.76 is the closing price of our Common Stock on June 27, 2025, the last trading day for the payroll date for the pay period ending June 27, 2025.

SEC source: 0000950170-25-091637 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,406

F1 · security: Reflects the executive's 2024 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a 30-day lockup restriction with 100% of the award released on July 18, 2025.

F2 · price: $4.47 was the fair market value of Agenus Common Stock on June 18, 2025, the stock issuance date.

SEC source: 0000950170-25-091632 · ownership.xml · nonDerivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,478

F1 · security: Reflects the executive's 2024 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 100% of the award released on July 18, 2025.

F2 · price: $4.47 was the fair market value of Agenus Common Stock on June 18, 2025, the stock issuance date.

SEC source: 0000950170-25-091630 · ownership.xml · nonDerivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,116

F1 · security: Reflects the executive's 2024 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a 30-day lockup restriction with 100% of the award released on July 18, 2025.

F2 · price: $4.47 is the closing price of our Common Stock on June 18, 2025, the stock issuance date.

SEC source: 0000950170-25-088492 · ownership.xml · derivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Options were granted on May 28, 2025 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 17, 2025. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on May 28, 2026 and the balance vesting in equal quarterly installments thereafter.

SEC source: 0000950170-25-088505 · ownership.xml · derivative · entry 2

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-05-28

F2 · derivative.exercise_date: Options were granted on May 28, 2025 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 17, 2025. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests on the one-year anniversary of the grant date.

SEC source: 0000950170-25-088505 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 750

Underlying: Common Stock · 750 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Options were granted on May 28, 2025 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 17, 2025. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on May 28, 2026, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0000950170-25-088506 · ownership.xml · derivative · entry 2

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-05-28

F2 · derivative.exercise_date: Options were granted on May 28, 2025 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 17, 2025. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests on the one-year anniversary of the grant date.

SEC source: 0000950170-25-088506 · ownership.xml · derivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 750

Underlying: Common Stock · 750 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Options were granted on May 28, 2025 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 17, 2025. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on May 28, 2026, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0000950170-25-088504 · ownership.xml · derivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Options were granted on May 28, 2025 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 17, 2025. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests on the one-year anniversary of the grant date.

SEC source: 0000950170-25-088491 · ownership.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,250

Underlying: Common Stock · 7,250 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Options were granted on May 28, 2025 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 17, 2025. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on May 28, 2026 and the balance vesting in equal quarterly installments thereafter.

SEC source: 0000950170-25-095865 · ownership.xml · derivative · entry 2

HARRISON THOMAS L · CIK 0001247340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 17,500 shares

Expires 2035-05-28

F3 · derivative.exercise_date: Options were granted on May 28, 2025 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 17, 2025. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests on the one-year anniversary of the grant date.

SEC source: 0000950170-25-087378 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,009

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 13, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.70 is the closing price of our Common Stock on June 13, 2025, the last trading day for the payroll date for the pay period ending June 13, 2025.

SEC source: 0000950170-25-080903 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,529

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 30, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.43 is the closing price of our Common Stock on May 30, 2025, the last trading day for the payroll date for the pay period ending May 30, 2025.

SEC source: 0000950170-25-075159 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,750

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 16, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.48 is the closing price of our Common Stock on May 16, 2025, the last trading day for the payroll date for the pay period ending May 16, 2025.

SEC source: 0000950170-25-063521 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,060

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 2, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.11 is the closing price of our Common Stock on May 2, 2025, the last trading day for the payroll date for the pay period ending May 2, 2025.

SEC source: 0000950170-25-064636 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,738

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending May 2, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.11 is the closing price of our Common Stock on May 2, 2025, the payroll date for the pay period ending May 2, 2025.

SEC source: 0000950170-25-056720 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,800

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 18, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $2.08 is the closing price of our Common Stock on April 17, 2025, the last trading day for the payroll date for the pay period ending April 18, 2025.

SEC source: 0000950170-25-063522 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,157

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending April 18, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $2.08 is the closing price of our Common Stock on April 17, 2025, the payroll date for the pay period ending April 18, 2025.

SEC source: 0000950170-25-052051 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,914

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 4, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $1.56 is the closing price of our Common Stock on April 4, 2025, the payroll date for the pay period ending April 4, 2025.

SEC source: 0000950170-25-052895 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,288

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending April 4, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $1.56 is the closing price of our Common Stock on April 4, 2025, the payroll date for the pay period ending April 4, 2025.

SEC source: 0000950170-25-049296 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,459.668

Underlying: Common Stock · 3,255.58 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $2.88 per Deferred Stock Unit acquired on April 1, 2025. The price of each Deferred Stock Unit acquired on April 1, 2025 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-25-050373 · ownership.xml · nonDerivative · entry 1

HARRISON THOMAS L · CIK 0001247340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,898

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive their director fees in shares of Ageuns' common stock.

F2 · price: $2.88 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0000950170-25-043816 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,626

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 21, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $1.61 is the closing price of our Common Stock on March 21, 2025, the payroll date for the pay period ending March 21, 2025.

SEC source: 0000950170-25-046050 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,129

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending March 21, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $1.61 is the closing price of our Common Stock on March 21, 2025, the payroll date for the pay period ending March 21, 2025.

SEC source: 0000950170-25-037126 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,383

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 7, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $2.35 is the closing price of our Common Stock on March 7, 2025, the payroll date for the pay period ending March 7, 2025.

SEC source: 0000950170-25-043817 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,646

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending March 7, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $2.35 is the closing price of our Common Stock on March 7, 2025, the payroll date for the pay period ending March 7, 2025.

SEC source: 0000950170-25-026617 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,051

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 21, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.32 is the closing price of our Common Stock on February 21, 2025, the payroll date for the pay period ending February 21, 2025.

SEC source: 0000950170-25-033526 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,318

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending February 21, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.32 is the closing price of our Common Stock on February 21, 2025, the payroll date for the pay period ending February 21, 2025.

SEC source: 0000950170-25-037127 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,237

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending February 21, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.32 is the closing price of our Common Stock on February 21, 2025, the payroll date for the pay period ending February 21, 2025.

SEC source: 0000950170-25-018064 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,568

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 7, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.50 is the closing price of our Common Stock on February 7, 2025, the payroll date for the pay period ending February 7, 2025.

SEC source: 0000950170-25-022204 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,692

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Buell's salary for the pay period ending February 7, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $3.50 is the closing price of our Common Stock on February 7, 2025, the payroll date for the pay period ending February 7, 2025.

SEC source: 0000950170-25-009792 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,317

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending January 24, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.57 is the closing price of our Common Stock on January 24, 2025, the payroll date for the pay period ending January 24, 2025.

SEC source: 0000950170-25-010023 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,446

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents the gross amount of Dr. Buell's salary for the pay period ending January 24, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.57 is the closing price of our Common Stock on January 24, 2025, the payroll date for the pay period ending January 24, 2025.

SEC source: 0000950170-25-013409 · ownership.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,176

F1 · security: At her request and with the approval of the Agenus Inc. Compensation Committee, a portion of Jennifer Buell's salary is being paid in stock, in lieu of cash. The amount reported herein represents payment of tax liability by withholding securities incident to the receipt of securities issued in accordance with Rule 16b-3, for the pay period ending January 24, 2025.

F2 · price: $3.57 is the closing price of our Common Stock on January 24, 2025, the payroll date for the pay period ending January 24, 2025.

SEC source: 0000950170-25-004815 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,148

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending January 10, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.12 is the closing price of our Common Stock on January 10, 2025, the payroll date for the pay period ending January 10, 2025.

SEC source: 0000950170-25-000406 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,204.083

Underlying: Common Stock · 2,532.661 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.70 per Deferred Stock Unit acquired on January 2, 2025. The price of each Deferred Stock Unit acquired on January 2, 2025 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-25-000403 · ownership.xml · derivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,206.567

Underlying: Common Stock · 6,416.074 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.70 per Deferred Stock Unit acquired on January 2, 2025. The price of each Deferred Stock Unit acquired on January 2, 2025 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-24-141123 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,371

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending December 27, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $2.75 is the closing price of our Common Stock on December 27, 2024, the payroll date for the pay period ending December 27, 2024.

SEC source: 0000950170-24-136622 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,440

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending December 13, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.05 is the closing price of our Common Stock on December 13, 2024, the payroll date for the pay period ending December 13, 2024.